MITF: master regulator of melanocyte development and melanoma oncogene

Trends in Molecular Medicine

Volumn 12, Issue 9, 2006, Pages 406-414

  Levy, Carmit ^a   Khaled, Mehdi ^a   Fisher, David E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR;

CANCER GROWTH; CELL LINEAGE; CELL MATURATION; GENE CONTROL; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENETIC MODEL; GENETIC TRANSCRIPTION; HEALTH SURVEY; HUMAN; MELANOCYTE; MELANOMA; NONHUMAN; ONCOGENE; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION;

ALTERNATIVE SPLICING; ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HUMANS; MELANOCYTES; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENES; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION, GENETIC;

EID: 33747882661     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.07.008     Document Type: Review

References (102)

1. Hodgkinson C.A., et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74 (1993) 395-404
2. Widlund H.R., and Fisher D.E. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 22 (2003) 3035-3041
3. Steingrimsson E., et al. Melanocytes and the microphthalmia transcription factor network. Annu. Rev. Genet. 38 (2004) 365-411
4. Hemesath T.J., et al. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 8 (1994) 2770-2780
5. Bentley N.J., et al. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol. 14 (1994) 7996-8006
6. Yasumoto K., et al. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol. Cell. Biol. 14 (1994) 8058-8070
7. Steingrimsson E., et al. The bHLH-Zip transcription factor Tfeb is essential for placental vascularization. Development 125 (1998) 4607-4616
8. Steingrimsson E., et al. Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 4477-4482
9. Price E.R., et al. Alpha-melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J. Biol. Chem. 273 (1998) 33042-33047
10. Bertolotto C., et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J. Cell Biol. 142 (1998) 827-835
11. Goding C.R. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 14 (2000) 1712-1728
12. Hershey C.L., and Fisher D.E. Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene 347 (2005) 73-82
13. Fuse N., et al. Identification of a melanocyte-type promoter of the microphthalmia-associated transcription factor gene. Biochem. Biophys. Res. Commun. 219 (1996) 702-707
14. Jacquemin P., et al. The transcription factor onecut-2 controls the microphthalmia-associated transcription factor gene. Biochem. Biophys. Res. Commun. 285 (2001) 1200-1205
15. Yasumoto K., et al. Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J. 21 (2002) 2703-2714
16. Saito H., et al. Melanocyte-specific microphthalmia-associated transcription factor isoform activates its own gene promoter through physical interaction with lymphoid-enhancing factor 1. J. Biol. Chem. 277 (2002) 28787-28794
17. Huber W.E., et al. A tissue-restricted cAMP transcriptional response: SOX10 modulates α-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes. J. Biol. Chem. 278 (2003) 45224-45230
18. Dorsky R.I., et al. Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. Genes Dev. 14 (2000) 158-162
19. Takeda K., et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J. Biol. Chem. 275 (2000) 14013-14016
20. Widlund H.R., et al. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J. Cell Biol. 158 (2002) 1079-1087
21. Watanabe A., et al. Epistatic relationship between Waardenburg syndrome genes MITF and PAX3. Nat. Genet. 18 (1998) 283-286
22. Kamaraju A.K., et al. Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. J. Biol. Chem. 277 (2002) 15132-15141
23. mi/mi mice. Mol. Cell 8 (2001) 749-758
24. Wu M., et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14 (2000) 301-312
25. Takeda K., et al. Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is a phosphorylation site with functional significance. Hum. Mol. Genet. 9 (2000) 125-132
26. Mansky K.C., et al. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-κB ligand signaling. J. Biol. Chem. 277 (2002) 11077-11083
27. Price E.R., et al. Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia. J. Biol. Chem. 273 (1998) 17983-17986
28. Miller A.J., et al. Sumoylation of MITF and its related family members TFE3 and TFEB. J. Biol. Chem. 280 (2005) 146-155
29. Murakami H., and Arnheiter H. Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner. Pigment Cell Res. 18 (2005) 265-277
30. Larribere L., et al. The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev. 19 (2005) 1980-1985
31. Levy C., et al. A new role for the STAT3 inhibitor, PIAS3: a repressor of microphthalmia transcription factor. J. Biol. Chem. 277 (2002) 1962-1966
32. Levy C., et al. Role played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3. Mol. Cell. Biol. 23 (2003) 9073-9080
33. Razin E., et al. Suppression of microphthalmia transcriptional activity by its association with protein kinase C-interacting protein 1 in mast cells. J. Biol. Chem. 274 (1999) 34272-34276
34. Tassabehji M., et al. Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nat. Genet. 8 (1994) 251-255
35. Price E.R., and Fisher D.E. Sensorineural deafness and pigmentation genes: melanocytes and the Mitf transcriptional network. Neuron 30 (2001) 15-18
36. Lang D., et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433 (2005) 884-887
37. Lang D., et al. Pax3 is required for enteric ganglia formation and functions with Sox10 to modulate expression of c-ret. J. Clin. Invest. 106 (2000) 963-971
38. Sanchez-Martin M., et al. SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum. Mol. Genet. 11 (2002) 3231-3236
39. Hemesath T.J., et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391 (1998) 298-301
40. mi/mi mice. Mol. Cell 8 (2001) 749-758
41. Steingrimsson E., et al. Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat. Genet. 8 (1994) 256-263
42. Lerner A.B., et al. A mouse model for vitiligo. J. Invest. Dermatol. 87 (1986) 299-304
43. Nishimura E.K., et al. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 307 (2005) 720-724
44. Steingrimsson E., et al. The semidominant Mi(b) mutation identifies a role for the HLH domain in DNA binding in addition to its role in protein dimerization. EMBO J. 15 (1996) 6280-6289
45. Hornyak T.J., et al. Transcription factors in melanocyte development: distinct roles for Pax-3 and Mitf. Mech. Dev. 101 (2001) 47-59
46. Nishimura E.K., et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416 (2002) 854-860
47. Steingrimsson E., et al. Melanocyte stem cell maintenance and hair graying. Cell 121 (2005) 9-12
48. Tsao H., et al. Management of cutaneous melanoma. N. Engl. J. Med. 351 (2004) 998-1012
49. Bowden G.T. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat. Rev. Cancer 4 (2004) 23-35
50. Merlino G., and Noonan F.P. Modeling gene-environment interactions in malignant melanoma. Trends Mol. Med. 9 (2003) 102-108
51. Chin L., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400 (1999) 468-472
52. Yamazaki F., et al. Development of a new mouse model (xeroderma pigmentosum a-deficient, stem cell factor-transgenic) of ultraviolet B-induced melanoma. J. Invest. Dermatol. 125 (2005) 521-525
53. Patton E.E., et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15 (2005) 249-254
54. Dell H. Melanoma: stripey surrogates. Nat. Rev. Cancer 5 (2005) 246
55. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
56. Rodolfo M., et al. Genetic progression of metastatic melanoma. Cancer Lett. 214 (2004) 133-147
57. Eskandarpour M., et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. J. Cancer 115 (2005) 65-73
58. Chin L., et al. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci. 23 (1998) 291-296
59. Zuo L., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12 (1996) 97-99
60. Marini A., et al. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J. Invest. Dermatol. 126 (2006) 422-431
61. Tsao H., et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122 (2004) 337-341
62. Soengas M.S., and Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 22 (2003) 3138-3151
63. McGill G.G., et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109 (2002) 707-718
64. Chudnovsky Y., et al. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat. Genet. 37 (2005) 745-749
65. Garraway L.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
66. Miller A.J., et al. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 64 (2004) 509-516
67. Salti G.I., et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 60 (2000) 5012-5016
68. Selzer E., et al. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res. 62 (2002) 2098-2103
69. Vachtenheim J., et al. Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. J. Invest. Dermatol. 117 (2001) 1505-1511
70. King R., et al. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for melanoma diagnosis. Am. J. Pathol. 155 (1999) 731-738
71. Granter S.R., et al. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am. J. Dermatopathol. 23 (2001) 185-189
72. Granter S.R., et al. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl. Immunohistochem. Mol. Morphol. 10 (2002) 47-51
73. Ganss R., et al. The mouse tyrosinase gene. Promoter modulation by positive and negative regulatory elements. J. Biol. Chem. 269 (1994) 29808-29816
74. Bentley N.J., et al. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol. 14 (1994) 7996-8006
75. Yasumoto K., et al. Transcriptional activation of the melanocyte-specific genes by the human homolog of the mouse Microphthalmia protein. J. Biochem. (Tokyo) 118 (1995) 874-881
76. Yasumoto K., et al. Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase family genes. J. Biol. Chem. 272 (1997) 503-509
77. Lowings P., et al. Positive and negative elements regulate a melanocyte-specific promoter. Mol. Cell. Biol. 12 (1992) 3653-3662
78. Bertolotto C., et al. Regulation of tyrosinase gene expression by cAMP in B16 melanoma cells involves two CATGTG motifs surrounding the TATA box: implication of the microphthalmia gene product. J. Cell Biol. 134 (1996) 747-755
79. Newton J.M., et al. Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism. OCA4. Am. J. Hum. Genet. 69 (2001) 981-988
80. Du J., and Fisher D.E. Identification of Aim-1 as the underwhite mouse mutant and its transcriptional regulation by MITF. J. Biol. Chem. 277 (2002) 402-406
81. Du J., et al. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am. J. Pathol. 163 (2003) 333-343
82. Jacobs J.J., et al. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 26 (2000) 291-299
83. Carreira S., et al. The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J. Biol. Chem. 275 (2000) 21920-21927
84. Vance K.W., et al. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 65 (2005) 2260-2268
85. Du J., et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6 (2004) 565-576
86. Busca R., et al. Hypoxia-inducible factor 1α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J. Cell Biol. 170 (2005) 49-59
87. Bell E.L., et al. Mitochondrial regulation of oxygen sensing. Mitochondrion 5 (2005) 322-332
88. Carreira S., et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433 (2005) 764-769
89. Loercher A.E., et al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell Biol. 168 (2005) 35-40
90. Sato S., et al. CBP/p300 as a co-factor for the Microphthalmia transcription factor. Oncogene 14 (1997) 3083-3092
91. de la Serna I.L., et al. The microphthalmia-associated transcription factor (MITF) requires SWI/SNF enzymes to activate melanocyte specific genes. J. Biol. Chem. (2006) 10.1074/jbc.M512052200
92. McGill G.G., et al. c-Met expression is regulated by Mitf in the melanocyte lineage. J. Biol. Chem. 281 (2006) 10365-10373
93. Sidhar S.K., et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum. Mol. Genet. 5 (1996) 1333-1338
94. Clark J., et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15 (1997) 2233-2239
95. Weterman M.A., et al. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 15294-15298
96. Ladanyi M., et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20 (2001) 48-57
97. Kuiper R.P., et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum. Mol. Genet. 12 (2003) 1661-1669
98. Davis I.J., et al. Cloning of an α-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6051-6056
99. Davis I.J., et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 9 (2006) 473-484
100. Fuse N., et al. Identification of a melanocyte-type promoter of the microphthalmia-associated transcription factor gene. Biochem. Biophys. Res. Commun. 219 (1996) 702-707
101. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
102. Feige E., et al. MITF, critical regulator of the melanocyte lineage. In: Leong V.J.H.a.S.P.L. (Ed). From Melanocytes to Melanoma: The Progression to Malignancy (2005), Humana Press Inc 51-69